FDG-PET May Pick Up High-Risk Early NSCLC

April 11, 2013

A positive fluorodeoxyglucose PET (FDG-PET) scan predicted significantly worse survival in patients with stage IA non-small cell lung cancer (NSCLC), suggesting a potential to identify candidates for adjuvant chemotherapy, a retrospective analysis showed.

Overall, patients with stage I disease and a positive PET scan had a median 5-year survival of 67% compared with 80% in patients with a negative PET.